4.5 Article

Enteral supplement enriched with glutamine, fiber, and oligosaccharide attenuates experimental colitis in mice

Journal

NUTRITION
Volume 29, Issue 3, Pages 549-555

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.nut.2012.09.007

Keywords

GFO; Ulcerative colitis; Dextran sulfate sodium; Interleukin-1 beta; Glucagon-like peptide

Funding

  1. Ministry of Education, Culture, Sports, Science, and Technology of Japan
  2. Kyoto University Global CUE Program, Center for Frontier Medicine
  3. Grants-in-Aid for Scientific Research [23617009, 25461345, 22590975] Funding Source: KAKEN

Ask authors/readers for more resources

Objective: Ulcerative colitis is a chronic recurrent disease characterized by acute inflammation of the colonic mucosa. In Japan, a dietary supplementation product enriched with glutamine, dietary fiber, and oligosaccharide (GFO) is widely applied for enteral nutrition support. These three components have been suggested to improve intestinal health. In this study, we investigated whether GFO has suppressive effects on mucosal damage in ulcerative colitis in an experimental mouse model. Methods: C57BL/6 mice received 2.5% dextran sulfate sodium in drinking water for 5 d to induce colitis. Then, they were given 0.25 mL of GFO or a 20% glucose solution twice daily for 10 d. Another set of mice receiving unaltered drinking water was used as the normal control group. Results: The body weight loss and disease activity index were significantly lower in the GFO-treated mice compared with the glucose-treated mice (P < 0.05). The decrease in colon length induced by dextran sulfate sodium was significantly alleviated in GFO-treated mice compared with glucose-treated mice (P < 0.01). In addition, the histologic findings showed that intestinal inflammation was significantly attenuated in mice treated with GFO. Furthermore, treatment with GFO significantly inhibited the dextran sulfate sodium-induced increase in the mRNA expression of interleukin-1 beta. Conclusion: These results suggest that GFO has potential therapeutic value as an adjunct therapy for ulcerative colitis. (C) 2013 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available